An observational study in The Aim of This Project is to Develop and Validate NTCP-models for Complications After nCRT (and Surgical Resection), sponsored by University Medical Center Groningen. Recruiting at 8 sites in Netherlands. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-04-16.
Sponsored by University Medical Center Groningen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Esophageal Neoplasms by University Medical Center Groningen — 8 open to participants now, 8 under way, none of them phase 3. Esophageal Neoplasms · University Medical Center Groningen.
Among the 16 studies in Esophageal Neoplasms by University Medical Center Groningen, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 14th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →8 of the 16 studies in Esophageal Neoplasms by University Medical Center Groningen are open now, in 3 countries. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Belgium, Netherlands, United Kingdom
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 1
First in 2009; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 2,000 is above the median of 200 across 433 observational studies indexed under Esophageal Neoplasms.
Median enrollment 15 across the 9 interventional studies, 100 across the 7 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 175 are open to participants now.
2 of the studies in Esophageal Neoplasms by University Medical Center Groningen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07108855University Medical Center GroningenDetection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection | 2027-06-01 |
| NCT04986293University Medical Center GroningenCPAP or BiPAP for Motion Mitigation During Radiotherapy | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Esophageal Neoplasms by University Medical Center Groningen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this project is to develop and validate NTCP-models for complications after nCRT (and surgical resection), that can be uses for model-based dose optimization for PhRT and PRT, and for model-based selection for PRT, in patients with esophageal cancer
Plan of investigation
In the present project we aim to evaluate two potential strategies to predict and consider a broad spectrum of complications for radiotherapy plan optimization and patient selection:
A comprehensive set of separate NTCP-models for several cardiopulmonary and post-operative complications after nCRT, which results in an NTCP-profile.
A single multivariable NTCP-model for a so-called Complication Sum Score (CSS), which is a single composite complication endpoint including all complications after nCRT, weighted depending on severity and impact.
These prediction models can be used for RT plan optimization and patient selection.
In order to develop these prediction models the project consortium brings together existing prospective data registries for esophageal cancer, namely the Dutch Upper GI Cancer Audit (DUCA) and the Dutch Cancer Registry (NKR) (as well as the POCOP study).
The data of these registries will be linked to a retrospective radiotherapy database using the ProTRAIT infrastructure, resulting in a dataset of over 2000 patients.
In this retrospective cohort study, we will focus on esophageal cancer patients who were treated with nCRT, and for whom an esophagectomy was intended. We will include the patients who received nCRT and the esophagectomy in one of the participating centers. Patients who only received nCRT in one of the participating centers and for whom surgical resection was omitted will be included as well. Detailed eligibility criteria can be found in that section.
Eligible patients will be identified by the Dutch Cancer Registry. The surviving patients will be asked to provide informed consent for participation in this study, permission to combine the different data registries and for future use of their data. Patients who died will be included as well, unless they objected agains the use of there data in the participating centers.
Of the participating patients, the radiotherapy plan-CT and treatment plans (i.e. RTplan, RT struct, RT dose), will be pseudo-anonymized, uploaded and transferred to the UMCG data platform, by the participating radiotherapy centers.
A third trusted party, Zorg TTP, will be responsible for the pseudonymization of the three data sources; the Dutch upper GI cancer audit (DUCA), the Dutch Cancer Registry (NKR) and the RTregistry. After that the linkage will be performed at the UMCG.
Patients with esophageal cancer, treated with nCRT between 2015-2021 in the participating centers. See eligibility criteria above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
follow up
Multivariable NTCP models will be developed for the prediction of the following
Postoperative complications (graded by ECCG classification (3) ): Atrial fibrillation ≥grade 2 Pneumonia ≥grade 2 Respiratory failure requiring re-intubation Anastomotic leakage ≥ grade 2
Time frame: Within 90 days after surgery
Cardiac events grade II or higher (CTCAE v 5.0), including:
Pericardial effusion Myocardial infarction and other acute coronary events Heart failure Pericardial effusion Myocardial infarction and other acute coronary events Heart failure Atrial fibrillation
Time frame: 1 and 2 year after nCRT
Mortality
Mortality
Time frame: 1 and 2 year after nCRT
Complication Sum Score, that will be determined in Delphi consensus
Complication Sum Score, that will be determined in Delphi consensus
Time frame: 1 year after nCRT
Patient-rated dysphagia
Patient-rated dysphagia
Time frame: Up to 30 days after nCRT
Patient-rated nausea
Patient-rated nausea
Time frame: Up to 30 day after nCRT
Patient-rated fatigue / daily functioning
Patient-rated fatigue / daily functioning
Time frame: Up to 6 months after nCRT
Hospitalization after esophagectomy (days)
Hospitalization after esophagectomy (days)
Time frame: Hospitalization after esophagectomy, average 12 days
Intensive care unit stay after esophagectomy (days)
Intensive care unit stay after esophagectomy (days)
Time frame: Intensive care unit stay after esophagectomy, average 1.5 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Jun 2025, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen →